Omega-3 Polyunsaturated Fatty Acids Intake to Regulate Helicobacter pylori-Associated Gastric Diseases as Nonantimicrobial Dietary Approach

Biomed Res Int. 2015;2015:712363. doi: 10.1155/2015/712363. Epub 2015 Aug 3.

Abstract

Omega-3 polyunsaturated fatty acids (n-3 PUFAs), commonly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have been acknowledged as essential long-chain fatty acids imposing either optimal health promotion or the rescuing from chronic inflammatory diseases such as atherosclerosis, fatty liver, and various inflammatory gastrointestinal diseases. Recent studies dealing with EPA and DHA have sparked highest interests because detailed molecular mechanisms had been documented with the identification of its receptor, G protein coupled receptor, and GPR120. In this review article, we have described clear evidences showing that n-3 PUFAs could reduce various Helicobacter pylori- (H. pylori-) associated gastric diseases and extended to play even cancer preventive outcomes including H. pylori-associated gastric cancer by influencing multiple targets, including proliferation, survival, angiogenesis, inflammation, and metastasis. Since our previous studies strongly concluded that nonantimicrobial dietary approach for reducing inflammation, for instance, application of phytoceuticals, probiotics, natural products including Korean red ginseng, and walnut plentiful of n-3 PUFAs, might be prerequisite step for preventing H. pylori-associated gastric cancer as well as facilitating the rejuvenation of precancerous atrophic gastritis, these beneficial lipids can restore or modify inflammation-associated lipid distortion and correction of altered lipid rafts to send right signaling to maintain healthy stomach even after chronic H. pylori infection.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Docosahexaenoic Acids / therapeutic use
  • Eicosapentaenoic Acid / therapeutic use
  • Fatty Acids, Omega-3 / therapeutic use*
  • Helicobacter Infections / diet therapy*
  • Helicobacter Infections / metabolism
  • Helicobacter pylori / drug effects*
  • Helicobacter pylori / pathogenicity
  • Humans
  • Inflammation / diet therapy*
  • Inflammation / metabolism
  • Inflammation / pathology
  • Probiotics / therapeutic use

Substances

  • Fatty Acids, Omega-3
  • Docosahexaenoic Acids
  • Eicosapentaenoic Acid